Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag, French Cancer Institute Partner to Assess Pharmacogenomic Value of miRNA

NEW YORK (GenomeWeb News) – Theranostics and in vitro diagnostics firm Theradiag today announced a partnership with the Regional Cancer Institute of Montpellier in France to assess the role of microRNA in predicting response to therapies for colorectal cancer.

The partners will develop theranostic tools for the screening and monitoring of colorectal cancer as part of the deal, which aims to evaluate the expression and predictive role of miRNA in treatment response to radio- and chemotherapies for the disease. Theradiag will identify biomarkers that may be developed into theranostic assays, the partners said.

Financial and other terms of the deal were not disclosed.

Theradiag also announced that it opened a new laboratory dedicated to applied research for the development of miRNA-based assays within the Cap Alpha incubator in Montpellier.

Theradiag bought miRNA-based technology firm Prestizia a year ago.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.